Legal Opinion
Hochendoner v. Genzyme Corp.
District Court, D. Massachusetts
Decided March 25, 2015No. Civil Action Nos. 11-10739-DPW, 13-11336 DPWPublishedCited by 7 opinions
1Opinion of the Court
MEMORANDUM AND ORDER
DOUGLAS P. WOODLOCK, District Judge.
Genzyme Corporation is the manufacturer of Fabrazyme®, the only treatment for Fabry disease approved by the Food and Drug Administration (“FDA”) available in the United States. In June 2009, due to various problems at its manufacturing facility, Genzyme was unable to manufacturer sufficient Fabrazyme® to meet the demand for the drug. During this shortage, Genzyme adopted a rationing plan under which United States Fabry sufferers would be allocated less than the recommended dose, and newly diagnosed Fabry patients would not be prescribed…
2Cases cited48 opinions
- Ashcroft v. IqbalSupreme Court of the United States · 2009
- Bell Atlantic Corp. v. TwomblySupreme Court of the United States · 2007
- Conley v. GibsonSupreme Court of the United States · 1957
- Bivens v. Six Unknown Named Agents of Federal Bureau of NarcoticsSupreme Court of the United States · 1971
- Swierkiewicz v. Sorema N. A.Supreme Court of the United States · 2002
43 more not listed; retrieve them via the Exa API.
3Cited by7 opinions
- Hochendoner v. Genzyme CorporationCourt of Appeals for the First Circuit · 2016
- Wilkins v. Genzyme CorporationCourt of Appeals for the First Circuit · 2024
- Evers v. Hologic, Inc.District Court, D. Massachusetts · 2025
- Mariafrancesca Gioia v. Teva Pharmaceuticals USA, Inc.District Court, E.D. New York · 2026
- Turner v. Modesto Police DepartmentDistrict Court, E.D. California · 2023
2 more not listed; retrieve them via the Exa API.